09445

The key to knowledge is in your (nitrile-gloved) hands

Already an ACS Member? Log in here

Basic

$0 Community Associate

ACS’s Basic Package keeps you connected with C&EN and ACS.

JOIN NOW

Standard

$80 Regular Members & Society Affiliates

ACS’s Standard Package lets you stay up to date with C&EN, stay active in ACS, and save.

Eligibility restrictions apply. Review ACS Membership Packages to see if you qualify.

JOIN NOW

Premium

$160 Regular Members & Society Affiliates
$55 Graduate Students
$25 Undergraduate Students

ACS’s Premium Package gives you full access to C&EN and everything the ACS Community has to offer.

ACS offers discounts for some countries outside the United States. This discount is shown at checkout, if applicable.

JOIN NOW

« Prev

November 14, 2016 Cover

Volume 94, Issue 45

After a controversial drug approval, biotech firms and patient advocacy groups look for a consensus on the design of trials for future drugs

Cover image:

Credit:

Full Article

Volume 94 | Issue 45

« Prev

After a controversial drug approval, biotech firms and patient advocacy groups look for a consensus on the design of trials for future drugs

Two hot start-ups are giving the biobased chemicals industry new life

Replacing flammable organic liquids with nonflammable inorganic solids would eliminate key battery hazard

Water

How do chemists’ salaries stack up?

ACS’s annual employment survey shows unemployment down and salaries steady in 2016
Reaction Dynamics

Periodic graphics: Why Li-ion batteries catch fire

Chemical educator and Compound Interest blogger Andy Brunning reveals reasons why the compact components sometimes burst into flame
Pharmaceuticals

Gene therapy is ready for its comeback

Clinical successes, focused start-ups, and pharma’s attention push genetic remedies closer to market
Sign up for C&EN must-read weekly newsletter

Email Address*

Contact us to opt out anytime